People with autoimmune skin diseases had significantly better cancer survival outcomes than others. Survival benefits were ...

Novartis' blockbuster immunology drug Cosentyx has disappointed in a phase 3 trial involving patients with giant cell ...

In fact, research shows that changing biologics is common. After two years, 1 in 4 people with psoriasis change from one biologic to another. Doing so can help improve your quality of life. Here ...

ORLANDO, FLORIDA / ACCESS Newswire / July 3, 2025 / RedChip Companies will air interviews with Fathom Holdings, Inc.

Cosentyx missed its main goal in a Phase 3 GCA study, but showed lower steroid use. Novartis plans full review of the trial ...

AbbVie has announced that it will be expanding its immunology capabilities by acquiring Capstan Therapeutics for up to $2.1bn ...

Medically reviewed by William Truswell, MD Jojoba oil from the Schisandra chinensis plant is used in skin products for its moisturizing, protective, and anti-inflammatory properties. It is similar in ...

Medically reviewed by Casey Gallagher, MD Eyebrow dandruff occurs when dead skin cells shed faster than usual. It causes white, yellow, or gray flakes around your brows. Seborrheic dermatitis, a skin ...

Patients with autoimmune skin diseases had improved survival after cancer treatment, suggesting a potential immunologic advantage and prompting further research into autoimmune-cancer interactions.

The GCAptAIN study did not meet its primary endpoint of sustained remission at Week 52 in adults with newly diagnosed or relapsing GCA1 ...

AnaptysBio, Inc. (NASDAQ:ANAB – Get Free Report) has been assigned an average recommendation of “Moderate Buy” from the ten ...

From morning aches to chilly toes, uncover the common foot problems you may be missing—and find out how to keep your feet ...